# EAA181: HCP commentary report

> 352 verified statements (14 from speakers with a confirmed clinical role) from 101 commentary sources · 13 findings · updated Oct 18, 2026

## Report

- Trial: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
- NCT ID: NCT04566328
- Registry: https://clinicaltrials.gov/study/NCT04566328
- Sponsor: ECOG-ACRIN Cancer Research Group
- Phase: Phase 3
- Status: Recruiting
- Drugs: bortezomib, dexamethasone, lenalidomide
- Indications: Multiple myeloma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-18
- Last checked: 2026-10-18
- Release hash: 62abfcbc36931a184523631fd32363c5318b0f415c2eec9a4587194362c57fba

## Counts

- HCP commentary sources screened: 246
- Sources cited by verified statements: 101
- Verified statements: 352
- From speakers with a confirmed clinical role: 14
- Findings: 13
- People found in screened sources: 12
- People identity-verified: 4
- Voices cited: 12

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

HCP commentary report on Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial (NCT04566328). Trial question: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation. Aspects: Primary endpoint: Consolidation overall survival (discussed, 4 verified views); Secondary endpoints (discussed, 6 verified views); Population and setting (discussed, 11 verified views); The comparison (discussed, 7 verified views); Safety and tolerability (discussed, 12 verified views); Design and conduct (discussed, 7 verified views); MRD as information versus a trigger for intensification (discussed, 19 verified views); Maintenance duration and conditions for stopping (discussed, 18 verified views); Dynamic fitness, transplant alternatives and older-patient applicability (discussed, 21 verified views); Comparator selection and cross-trial interpretation (discussed, 20 verified views); Marrow, blood, serum and imaging in response monitoring (discussed, 32 verified views); Dose, schedule and dexamethasone adaptation in routine care (discussed, 9 verified views); Research alternatives for response deepening and earlier immune therapy (discussed, 35 verified views); Risk definitions, prognostic work-up and precision-treatment selection (discussed, 25 verified views); Treatment access, specialist referral and representative evidence (discussed, 17 verified views); Supportive care, observation choices and patient decision support (discussed, 27 verified views); Trial dissemination and the gap between guidelines and active practice (discussed, 14 verified views). 246 sources screened, 102 cited. The sources reviewed for this edition only; not all HCPs or all public discussion.

## Open Medical Affairs question

What patient characteristics and response findings would make delayed bortezomib addition preferable to an upfront quadruplet or continued triplet?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The central question is who needs bortezomib, and when—not whether deeper responses justify intensification for everyone
- F2. Safety concerns are regimen- and time-dependent; neither efficacy nor toxicity is treated as a class-wide quadruplet effect
- F3. MRD is valued as prognostic information, but positivity is not an automatic mandate to escalate
- F4. Maintenance discontinuation attracts support, but neither the stopping time nor an MRD rule is settled
- F5. Fitness and transplant intent require reassessment; chronological age alone is an inadequate substitute
- F6. Cross-trial comparisons are challenged on population, schedule and censoring—not simply biology
- F7. Blood-based monitoring is discussed as complementary to marrow, not a validated replacement
- F8. Routine-care adaptation prioritizes sustainable doses and less dexamethasone
- F9. Bispecific and CAR T alternatives generate interest, but the trial-versus-standard-care boundary is explicit
- F10. Risk labels and precision-treatment tools are not treated as interchangeable or settled
- F11. Access and representation affect what treatment choices and prediction models can deliver
- F12. Supportive care and patient preferences are part of the treatment decision, not a fallback after disease-directed therapy
- F13. Trial awareness is visible, but repeated link sharing is not endorsement or evidence of uptake

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 17 | 20 | 4 | 2 | recorded | 2 |
| F2 | 26 | 18 | 2 | 3 | recorded | 2 |
| F3 | 20 | 17 | 4 | 0 | recorded | 2 |
| F4 | 20 | 17 | 4 | 2 | recorded | 2 |
| F5 | 24 | 16 | 3 | 3 | recorded | 2 |
| F6 | 20 | 16 | 2 | 4 | recorded | 2 |
| F7 | 31 | 25 | 3 | 1 | recorded | 2 |
| F8 | 9 | 6 | 3 | 1 | recorded | 2 |
| F9 | 35 | 27 | 2 | 4 | recorded | 2 |
| F10 | 25 | 24 | 5 | 5 | recorded | 2 |
| F11 | 17 | 10 | 2 | 2 | recorded | 2 |
| F12 | 28 | 13 | 2 | 2 | recorded | 2 |
| F13 | 14 | 109 | 92 | 2 | recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 10 | 3 | 2 | 0 | 2 | 21 | 11 | 1 post or article, 3 podcasts and video | yes |
| F2 | 10 | 4 | 2 | 9 | 1 | 30 | 10 | 1 post or article, 1 podcast or video | yes |
| F3 | 10 | 3 | 0 | 3 | 4 | 40 | 6 | 4 podcasts and video | yes |
| F4 | 8 | 4 | 2 | 0 | 6 | 27 | 7 | 4 podcasts and video | yes |
| F5 | 12 | 5 | 4 | 2 | 1 | 25 | 13 | 3 podcasts and video | yes |
| F6 | 4 | 6 | 0 | 7 | 3 | 22 | 10 | 1 post or article, 1 podcast or video | yes |
| F7 | 8 | 2 | 1 | 4 | 16 | 68 | 14 | 3 podcasts and video | yes |
| F8 | 4 | 2 | 1 | 0 | 2 | 9 | 4 | 3 podcasts and video | yes |
| F9 | 15 | 6 | 3 | 3 | 8 | 40 | 8 | 2 podcasts and video | yes |
| F10 | 13 | 5 | 1 | 1 | 5 | 29 | 6 | 5 podcasts and video | yes |
| F11 | 7 | 3 | 1 | 3 | 3 | 19 | 6 | 2 podcasts and video | yes |
| F12 | 10 | 0 | 1 | 2 | 15 | 37 | 15 | 2 podcasts and video | yes |
| F13 | 1 | 0 | 0 | 2 | 11 | 97 | 15 | 91 posts and articles, 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Consolidation overall survival: F1 (4 shared claims), F3 (1 shared claims)
- Secondary endpoints: F1 (3 shared claims), F2 (2 shared claims), F3 (1 shared claims)
- Population and setting: F1 (5 shared claims), F5 (6 shared claims), F10 (2 shared claims), F11 (1 shared claims), F13 (1 shared claims)
- The comparison: F1 (7 shared claims), F3 (1 shared claims), F6 (1 shared claims)
- Safety and tolerability: F2 (12 shared claims), F4 (1 shared claims)
- Design and conduct: F1 (2 shared claims), F5 (2 shared claims), F11 (1 shared claims), F13 (3 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 13 | Titles free |
| Detailed analysis | 14 sections | Paid |
| Verified statements with short source quotes and links | 352 | Paid |
| Trial aspects mapped | 17 | Free |
| Sources with links | 101 | Counts free |
| Speaker attribution for cited voices | 12 | Paid |

## Trial aspects

17 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Consolidation overall survival | discussed | 4 | 2 |
| Secondary endpoints | discussed | 6 | 1 |
| Population and setting | discussed | 11 | 3 |
| The comparison | discussed | 7 | 2 |
| Safety and tolerability | discussed | 12 | 2 |
| Design and conduct | discussed | 7 | 17 |
| MRD as information versus a trigger for intensification | discussed | 18 | 4 |
| Maintenance duration and conditions for stopping | discussed | 18 | 4 |
| Dynamic fitness, transplant alternatives and older-patient applicability | discussed | 21 | 2 |
| Comparator selection and cross-trial interpretation | discussed | 20 | 2 |
| Marrow, blood, serum and imaging in response monitoring | discussed | 32 | 3 |
| Dose, schedule and dexamethasone adaptation in routine care | discussed | 9 | 3 |
| Research alternatives for response deepening and earlier immune therapy | discussed | 35 | 2 |
| Risk definitions, prognostic work-up and precision-treatment selection | discussed | 25 | 5 |
| Treatment access, specialist referral and representative evidence | discussed | 17 | 2 |
| Supportive care, observation choices and patient decision support | discussed | 27 | 2 |
| Trial dissemination and the gap between guidelines and active practice | discussed | 14 | 92 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 234 | 92 |
| YouTube | 12 | 9 |

- Screened window: 2022-07-27 to 2026-10-15
- Cited window: 2022-07-27 to 2026-10-15
- Retrieved: 2026-10-18

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
- Registry: NCT04566328 (https://clinicaltrials.gov/study/NCT04566328)
- Study IDs: EAA181 · NCI-2020-06647 (CTRP (Clinical Trial Reporting Program)) · U10CA180820
- Sponsor: ECOG-ACRIN Cancer Research Group
- Collaborators: National Cancer Institute (NCI)
- Design: Phase 3 · interventional, randomized, sequential, phase3
- Status: Recruiting
- Enrollment: 1,450 (estimated)
- Start: 2021-02-24 (actual)
- Primary completion: 2027-12-31 (estimated)
- Primary endpoint: Consolidation overall survival (Time from Step 2 randomization at the start of consolidation to death or to the date last known alive, assessed up to 15 years)
- Intervention: Bortezomib (drug)
- Intervention: Daratumumab and Hyaluronidase-fihj (biological)
- Intervention: Dexamethasone (drug)
- Intervention: Lenalidomide (drug)
- Intervention: Quality-of-Life Assessment (other)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- Out of scope: 4 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
- 105 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are not a representative sample of all HCP opinion. Repeated posts from one author do not establish consensus or prescribing uptake.
- Many recording passages cannot be assigned confidently to a named individual. Their views are reported anonymously rather than inferred from a program, participant list or professional profile.
- No exact-trial publication or standalone protocol was available. Study descriptions in commentary must therefore remain speakers' accounts, and other-trial results must not be read as EQUATE outcomes.
- Some social-media conversations and one podcast were unavailable. Other passages in included recordings were not fully assessed, including parts of the discussion of early MRD-guided transplant omission, slow response and sustained negativity.
- The reported direction of BENEFIT's MRD comparison differs between Derman's post and the later podcast account. Both are preserved as source-specific statements rather than reconciled into a single result.
- Several numerical comparisons are approximate recollections or cross-trial observations. Censoring explanations, exposure interpretations and proposed reasons for age limits are hypotheses, not demonstrated analyses in this edition.
- Future stopping strategies, blood-monitoring algorithms, genetic prediction tools and earlier immune-therapy sequences remain conditional or investigational in the statements cited.
- The supplied registry description of the treatment comparison is abbreviated. The report does not reconstruct missing regimen details or infer current recruitment from an announcement's activation date.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-18: current edition

Last checked for new commentary 2026-10-18. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Deep (352 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (4 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/eaa181-nct04566328
- Agents: POST https://www.erudio.com/api/orders with {"report": "eaa181-nct04566328", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=eaa181-04566328

## Cite

Erudio Health. EAA181 (NCT04566328): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 18, 2026. https://www.erudio.com/reports/eaa181-nct04566328

## Machine access

- JSON: https://www.erudio.com/reports/eaa181-nct04566328.json
- Markdown: https://www.erudio.com/reports/eaa181-nct04566328.md
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "eaa181-04566328"}`